Month: October 2024
October 07, 2024
Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis
- Rapid epinephrine absorption with a time to reach the 100 pg/mL threshold concentration in 9 minutes after dosing
- Sustained pharmacokinetics (PK) with plasma epinephrine concentration remaining above 100 pg/mL for 2 hours post-dose, ensuring a durable treatment effect
- Safe and well tolerated, with only mild, transient, and self-resolving adverse events (AEs) reported
NORTH HAVEN, Conn., Oct. 07, 2024 (GLOBE NEWSWIRE) — Insignis Therapeutics, a leader in innovative allergy and anaphylaxis treatments, is excited to announce positive Phase 1 results for IN-001, an investigational liquid epinephrine sublingual spray for anaphylaxis. This study, A24-1889, demonstrated that IN-001 is highly effective and easy to use, offering a promising alternative to current needle-based treatments.
Read More